Activity of an engineered synthetic killer peptide on Leishmania major and Leishmania infantum promastigotes

Experimental Parasitology

Volumn 113, Issue 3, 2006, Pages 186-192

  Savoia, Dianella ^a   Scutera, Sara ^a   Raimondo, Stefania ^a   Conti, Stefania ^b   Magliani, Walter ^b   Polonelli, Luciano ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

DNA fragmentation; DNA, deoxyribonucleic acid; Electron microscopy; GFP, green fluorescent protein; Killer peptide; KP, killer peptide; L. infantum; L. major; TEM, transmission electron microscopy

Indexed keywords

ALANYLLYSYLVALYLTHREONYLMETHIONYLTHREONYLCYSTEINYLSERYLALANYLSERINE; DNA FRAGMENT; GREEN FLUORESCENT PROTEIN; KILLER DECAPEPTIDE; PEPTIDE; TOXIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BIOENGINEERING; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SYNTHESIS; IN VITRO STUDY; INTRACELLULAR SPACE; LC 50; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN SECRETION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIPROTOZOAL AGENTS; CELLULASES; DESIGNER DRUGS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, AGAR GEL; GREEN FLUORESCENT PROTEINS; INDICATORS AND REAGENTS; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; METHYLENE BLUE; MICROSCOPY, ELECTRON, TRANSMISSION; PEPTIDES; PERMEABILITY;

LEISHMANIA INFANTUM; LEISHMANIA MAJOR;

EID: 33744523292     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2006.01.002     Document Type: Article

References (39)

1. Bera A., Singh S., Nagaraj R., and Vaidya T. Induction of autophagic cell death in Leishmania donovani by antimicrobial peptides. Molecular and Biochemical Parasitology 127 (2003) 23-35
2. Brittingham A., Morrison C.J., McMaster W.R., McGwire B.S., Cang K., and Mosser D.M. Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis. Journal of Immunology 155 (1995) 3102-3111
3. Cenci E., Bistoni F., Mencacci A., Perito S., Magliani W., Conti S., Polonelli L., and Vecchiarelli A. A synthetic peptide as a novel anticryptococcal agent. Cellular Microbiology 6 (2004) 953-961
4. Conti S., Fanti F., Magliani W., Gerloni M., Bertolotti D., Salati A., Cassone A., and Polonelli L. Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies. Journal of Infectious Diseases 177 (1998) 807-811
5. Conti S., Magliani W., Arseni S., Frazzi R., Salati A., Ravanetti L., and Polonelli L. Inhibition by yeast killer toxin-like antibodies of oral Streptococci adhesion to tooth surfaces in an ex vivo model. Molecular Medicine 8 (2002) 313-317
6. Croft S.L., Barrett M.P., and Urbina J.A. Chemotherapy of trypanosomiases and leishmaniasis. Trends in Parasitology 21 (2005) 508-512
7. Descoteaux A., and Turco S.J. Glycoconjugates in Leishmania infectivity. Biochimica and Biophysica Acta 1455 (1999) 341-352
8. Desjeux P., and Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Annales of Tropical Medicine and Parasitology 97 Suppl. 1 (2003) 3-15
9. Guyard C., Dehecq E., Tissier J.P., Polonelli L., Dei-Cas E., Cailliez J.C., and Menozzi F.D. Involvement of β-glucans in the wide-spectrum antimicrobial activity of Williopsis saturnus var. mrakii MUCL 41968 killer toxin. Molecular Medicine 8 (2002) 686-694
10. Ha D.S., Schwarz J.K., Turco S.J., and Beverley S.M. Use of green fluorescent protein as a marker in transfected Leishmania. Molecular and Biochemical Parasitology 77 (1996) 57-64
11. Hammer K.A., Carson C.F., and Riley T.V. Antifungal effects of Maleleuca alternifolia (tea tree) oil and its components on Candida albicans, Candida glabrata and Saccharomyces cerevisiae. Journal of Antimicrobial Chemotherapy 53 (2004) 1081-1085
12. Holbrook T.W., Cook J.A., and Parker B.W. Immunization against Leishmania donovani: glucan as an adjuvant with killed promastigotes. American Journal of Tropical Medicine and Hygiene 30 (1981) 762-768
13. Jarecki-Black J.C., James E.R., Kirshtein J.W., Kirshtein J.D., and Glassman A.B. Leishmania donovani: immunization against infection as a function of parasite growth phase. American Journal of Tropical Medicine and Hygiene 35 (1986) 1117-1120
14. Lee N., Bertholet A.D., Debradant A., Muller J., Duncan R., and Nakhasi H.L. Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differentiation 9 (2002) 53-64
15. Luque-Ortega J.R., Saugar J.M., Chiva C., Andreu D., and Rivas L. Identification of new leishmanicidal peptide lead structures by automated real-time monitoring of changes in intracellular ATP. Biochemical Journal 375 (2003) 221-230
16. Magliani W., Conti S., De Bernardis F., Gerloni M., Bertolotti D., Mozzoni P., Cassone A., and Polonelli L. Therapeutic potential of anti-idiotypic single-chain antibodies with yeast killer toxin activity. Nature Biotechnology 15 (1997) 155-158
17. Magliani W., Conti S., Salati A., Arseni S., Ravanetti L., Frazzi R., and Polonelli L. Engineered killer mimotopes: New synthetic peptides for antimicrobial therapy. Current Medicinal Chemistry 11 (2004) 1793-1800
18. Mangoni M.L., Saugar J.M., Dellisanti M., Barra D., Simmaco M., and Rivas L. Temporins, small antimicrobial peptides with leishmanicidal activity. Journal of Biological Chemistry 280 (2005) 984-990
19. Marty P., Le Fichoux Y., Pratlong F., and Gari-Toussaint M. Human visceral leishmaniasis in Alpes-Maritimes, France: epidemiological characteristics for the period 1985-1992. Transaction of the Royal Society of Tropical Medicine and Hygiene 88 (1994) 33-34
20. McGwire B.S., Olson C.L., Tack B.F., and Engman D.M. Killing of African trypanosomes by antimicrobial peptides. Journal of Infectious Diseases 188 (2003) 146-152
21. Mengeling B.J., and Turco S.J. Microbial glycoconjugates. Current Opinion in Structural Biology 8 (1998) 572-577
22. Morales M.A., Cruz I., Rubio J.M., Chicharro C., Canavate C., Laguna F., and Alvar J. Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1. Journal of Infectious Diseases 185 (2002) 1533-1537
23. Obaid K.A., Ahmad S., Khan H.M., Madhi A.A., and Khanna R. Protective effect of L. donovani antigens using glucan as an adjuvant. International Journal of Immunopharmacology 11 (1989) 229-235
24. Ouellette M., Drummelsmith J., and Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resistance Updates 7 (2004) 257-266
25. Paris C., Loiseau P.M., Bories C., and Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrobial Agents and Chemotherapy 48 (2004) 852-859
26. Polonelli L., De Bernardis F., Conti S., Boccanera M., Gerloni M., Morace G., et al. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. Journal of Immunology 152 (1994) 3175-3182
27. Polonelli L., Séguy N., Conti S., Gerloni M., Bertolotti D., Cantelli C., et al. Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Clinical and Diagnostic Laboratory Immunology 4 (1997) 142-146
28. Polonelli L., Magliani W., Conti S., Bracci L., Lozzi L., Neri P., Ariani, et al. Therapeutic activity of an engineered synthetic killer anti-idiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infection and Immunity 71 (2003) 6205-6212
29. Savoia D., Avanzini C., Conti S., Magliani W., Frazzi R., and Polonelli L. In vitro leishmanicidal activity of a monoclonal antibody mimicking a yeast killer toxin. Journal of Eukaryotic Microbiology 49 (2002) 319-323
30. Savoia D., Avanzini C., Allice T., Callone E., Guella G., and Dini F. Antimicrobial activity of euplotin C, the sesquiterpene taxonomic marker from the marine ciliate Euplotes crassus. Antimicrobial Agents and Chemotherapy 48 (2004) 3828-3833
31. Seay M.B., Heard P.L., and Chaudhuri G. Surface Zn-proteinase as a molecule for defense of Leishmania mexicana amazonensis promastigotes against cytolysis inside macrophage phagolysosomes. Infection and Immunity 64 (1996) 5129-5137
32. Séguy N., Polonelli L., Dei-Cas E., and Cailliez J.C. Perspectives in the control of Pneumocystis infections by using Pichia anomala killer toxin-like anti-idiotypic antibodies. FEMS Immunology and Medical Microbiology 22 (1998) 145-149
33. Spath G.F., Epstein L., Leader B., Singer S.M., Avila M.A., Turco S.J., and Beverley S.M. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proceedings of the National Academy of Sciences United States of America 97 (2000) 9258-9263
34. Taylor A.G.R., and Evans D.A. Methods of Cultivating Parasites In Vitro (1978), Academic Press, New York p.55-58
35. Travassos L.R., Silva L.S., Rodrigues E.G., Conti S., Salati A., Magliani W., and Polonelli L. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. Journal of Antimicrobial Chemotherapy 54 (2004) 956-958
36. Turco S.J., Spath G.F., and Beverley S.M. Is lipophosphoglycan a virulence factor? A surprising diversity between Leishmania species. Trends in Parasitology 17 (2001) 223-226
37. Verma N.K., and Dey C.S. Possible mechanisms of miltefosine-mediated death of Leishmania donovani. Antimicrobial Agents and Chemotherapy 48 (2004) 3010-3015
38. WHO., 2005. Leishmaniasis. [Online.] http://www.who.int/tdr/diseases/leish/.
39. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395